Xcovery, a developer of next-generation targeted therapeutics for cancer, today announced the scheduled poster presentation of preliminary data from the Phase 1 trial of investigational agent X-396 in patients with solid tumors at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 30 - June 3, 2014.
Help employers find you! Check out all the jobs and post your resume.
